Medical News Today -
21 Feb 2014 12:00
VentriNova, a regenerative medicine company with a novel gene therapy product, has announced that the journal Science Translational Medicine has published the results of a preclinical study demonstrating the ability of VN-100 to regenerate heart muscle in large animals following a heart attack. The research was led by Dr. Hina Chaudhry, founder of VentriNova and Director of Cardiovascular Regenerative Medicine at Icahn School of Medicine at Mount Sinai.
Share this Article